X0202 SCHEDULE 13G/A 0001193125-23-131200 0001761158 XXXXXXXX LIVE 2 Ordinary Shares, CHF 0.01 par value per share 02/13/2026 0001953530 Oculis Holding AG H5870P102 Bahnhofstrasse 20 Zug V8 CH-6300 Rule 13d-1(d) BVCF IV, L.P. E9 0.00 2436902.00 0.00 2436902.00 2436902.00 N 4.14 PN Notes to Rows 6, 8 and 9: See Item 2(a) below. Notes to Row 11: Based on 58,932,987 Ordinary Shares issued and outstanding of the Issuer as of February 13, 2026. BEYEOTECH E9 0.00 2436902.00 0.00 2436902.00 2436902.00 N 4.14 CO Notes to Rows 6, 8 and 9: See Item 2(a) below. Notes to Row 11: Based on 58,932,987 Ordinary Shares issued and outstanding of the Issuer as of February 13, 2026. BVCF IV GP, Ltd. E9 0.00 2436902.00 0.00 2436902.00 2436902.00 N 4.14 PN Notes to Rows 6, 8 and 9: See Item 2(a) below. Notes to Row 11: Based on 58,932,987 Ordinary Shares issued and outstanding of the Issuer as of February 13, 2026. Zhi Yang F4 0.00 2436902.00 0.00 2436902.00 2436902.00 N 4.14 IN Notes to Rows 6, 8 and 9: See Item 2(a) below. Notes to Row 11: Based on 58,932,987 Ordinary Shares issued and outstanding of the Issuer as of February 13, 2026. Oculis Holding AG Bahnhofstrasse 20 Zug, V8, CH-6300 This statement is filed by (i) BVCF IV, L.P. ("Fund"), a limited partnership incorporated under the laws of the Cayman Islands, (ii) BEYEOTECH ("Beyeotech"), a company organized and existing under the laws of the Cayman Islands, (iii) BVCF IV GP, Ltd. ("GP"), a limited company incorporated under the laws of the Cayman Islands, and (iv) Mr. Zhi Yang, a director and sole shareholder of GP (Fund, Beyeotech, GP and Mr. Zhi Yang are collectively referred to as the "Reporting Persons"). Beyeotech directly holds the 2,436,902 Ordinary Shares being reported in this statement. Beyeotech is a wholly-owned subsidiary of Fund, GP is the general partner of Fund and Mr. Zhi Yang is the sole shareholder and director of GP. GP, by virtue of it being the general partner of Fund, may be deemed to have voting control and investment discretion over the securities held by Beyeotech. Mr. Zhi Yang, by virtue of being the director and sole shareholder of GP, may be deemed to have voting control and investment discretion over the securities held by Beyeotech. Each of the Reporting Persons has entered into a Joint Filing Agreement, dated April 28, 2023, pursuant to which such Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended. The address of the principal business office of Beyeotech is 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands. The address of the principal business office of each of Fund, GP and Mr. Zhi Yang is 763 Mengzi Road, Suite 2604, Shanghai, China 200023. See Row 4 of each cover page. Y See Row 9 of each cover page. See Row 11 of each cover page. See Row 5 of each cover page. See Row 6 of each cover page. See Row 7 of each cover page. See Row 8 of each cover page. N Y Y Y Y Y Y Joint Filing Agreement dated April 28, 2023 https://www.sec.gov/Archives/edgar/data/1761158/000119312523131200/d499516dex991.htm BVCF IV, L.P. By: BVCF IV GP, Ltd., its general partner /s/ Zhi Yang 03/27/2026 BEYEOTECH /s/ Bernard Yang Feng 03/27/2026 BVCF IV GP, Ltd. /s/ Zhi Yang 03/27/2026 Zhi Yang /s/ Zhi Yang 03/27/2026